`
`
`Andrew F. Calman, M.D., Ph.D.
`Premier Eyecare of San Francisco
`2480 Mission Street, Suite 212
`San Francisco, CA 94110
`(415) 648-3600 Fax (415) 648-0719
`
`E-mail: acalmanmd@gmail.com
`Website: www.premier-eyecare.com
`
`
`
`June 29, 2017
`
`
`Personal Information:
`
`
`Curriculum Vitae
`
`Year of birth: 1960
`
`State of birth: New York
`
`Languages (in decreasing order of proficiency): French, Spanish, Italian, German,
`Russian, Japanese, Dutch, Tagalog, Catalan, and Czech
`
`
`Education:
`
`
`Culver Military Academy, Culver, IN, 1974-1978
`
`
`
`Honors: Valedictorian, National Merit Scholarship, Regimental Executive Officer,
`ROTC Medal, Honor Council, Varsity Crew, Honors in Mathematics, History, and
`French
`
`Yale University, New Haven, CT, 1978-1982
`
`
`
`
`B.S. and M.S., Molecular Biophysics and Biochemistry, 1982
`Honors: Summa Cum Laude, Phi Beta Kappa, Distinction in the Major
`
`
`University of California, San Francisco, CA, 1982-1989
`
`
`M.D. and Ph.D. in Microbiology and Immunology, 1989
`Honors: Alpha Omega Alpha, Chancellor’s Fellowship, Dean's Prize for Student
`Research
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`0001
`
`MYLAN - EXHIBIT 1042
`Mylan Pharmaceuticals Inc. et al. v. Allergan, Inc.
`IPR2016-01127, -01128, -01129, -01130, -01131, & -01132
`
`

`

`
`
`
`
`Clinical Training:
`
`
`Resident in Internal Medicine, Kaiser Foundation Hospital, San Francisco, CA, June 26,
`1989-June 25, 1990 (program chairman Dr. Paul Feigenbaum)
`
`Resident in Ophthalmology, University of California, San Francisco, CA, July 1, 1990-
`June 30, 1993 (program chairman Dr. Stephen Kramer)
`
`
`Medical Licensure:
`
`
`California Physician and Surgeon License #G-069615 (expires 6/2016)
`
`Washington State Physician and Surgeon License #MD00031327 (expired 6/1999, not
`renewed)
`
`DEA #BC2432689 (expires 8/2017)
`
`UPIN #F51576
`
`Medi-Cal #00G696150
`
`
`Board Certification:
`
`
`Board Certified, American Board of Ophthalmology, 1994 (1st attempt).
`Recertified 2004 (1st attempt), Recertified 2013 (1st attempt). Recertification
`effective January 1, 2015, Expiration December 31, 2024.
`
`
`
`
`Faculty positions:
`
`
`Associate Clinical Professor of Ophthalmology, University of California, San Francisco,
`2005-present
`
`Assistant Clinical Professor of Ophthalmology, University of California, San Francisco,
`1995-2005
`
`Clinical Instructor of Ophthalmology, University of California, San Francisco, 1993-1995
`
`Clinical Faculty in Ophthalmology, California Pacific Medical Center, 2010-present
`
`
`
`
`
`
`
`
`
`
`
`
`
`0002
`
`

`

`
`
`
`
`
`
`
`Associate Clinical Professor of Family and Community Medicine, University of
`California, San Francisco, 2005-2014 (ophthalmology training was removed from
`the FCM curriculum in 2014)
`
`
`
`
`Clinical Practice:
`
`
`Private practice in Comprehensive Ophthalmology in association with Alejandro
`
`Zaffaroni, M.D., 1580 Valencia St., Suite 106, San Francisco, CA, 94110, from August 1,
`1993 to June 30, 1997; and solo in same location from July 1, 1997 to January 31, 2001.
`Practice moved to 3201 Mission Street on February 1, 2001, then to 2480 Mission St.,
`Suite 212 on September 8, 2015.
`
`Practice emphasizes small-incision cataract surgery, glaucoma, and retinal disease.
`
`
`
`
`
`
`Administrative Experience:
`
`
`
`
`U.S. Dept. of Health & Human Services, Center for Medicare and Medicaid
`Services:
`
`California Medicare Carrier Advisory Committee, ophthalmology representative,
`1996-2004. Helped author Local Medicare Review Policies on cataract surgery,
`ptosis repair, scanning computerized optic disk imaging.
`
`State of California, Department of Mental Health
`
` Expert Reviewer, Mental Health Services Act County Implementation
` Plans, 2006
`
`County of San Mateo, California, Department of Mental Health
`
`Chair, Children and Youth Committee, San Mateo County Mental
`Health Board, 2005-2007
`
`Co-Chair, Children’s Workgroup, Mental Health Services
`Agency Implentation Task Force (Proposition 63), 2005
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`0003
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Steering Committee, Mental Health Services
`Agency Implentation Task Force (Proposition 63), 2005
`
`American Academy of Ophthalmology:
`
`Health Policy Committee, 2004-2008
`
`
`
` Task Force on Subspecialty Certification, 2003-2004
`
`
`
`
`
`Executive Council, 2003-2008
`
`Executive Council (alternate), 2002-2003, 2010
`
`
`
`
`
`
`
`
`
`
`
`Executive Council Nominating Committee, 2005-2006
`
`Executive Council Deputy State Section Leader, 2007
`
`Author of Executive Council Advisory Recommendation establishing a
`curriculum for training residents in Ethics and Advocacy, adopted as
`official AAO policy 2003
`
`
`
`Legislative Key Contact, 2000-present
`
` Leadership Development Program, 2000-2001
`
`California Academy of Eye Physicians and Surgeons (formerly California Academy
`of Ophthalmology):
`
` President, 2010
`
` Vice-President for Finance and Administration, 2005-2006
`
` Chief Financial Officer, 2004-2005
`
` Executive Committee, 2004-2006, 2009-2011
`
` Vice President for Third Party Payor Liaison, 1998-1999
`
`
`
`
`0004
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Board of Councilors, 2006-2011
`
`
`
`
`
`Assistant Vice President for Third Party Payor Liaison, 1996-1997, 2000-2004
`
`Legislative Rapid Response Team, 2000. Assisted in negotiations of California
`Senate Bill 929, governing optometric scope of practice.
`
`Board of Directors, 1998-2006, 2008-2011
`
`
`
`
`California Medical Association:
`
` Chair, Reference Committee on Insurance and Physician Reimbursement, 2007
`
` Reference Committee on Insurance and Physician Reimbursement, 2004-2005
`
` House of Delegates (Alternate), 2002-2012
`
`Author of CMA House of Delegates Resolutions 703a-04 (Prescription
`Drug Re-Importation from Canada) and 704a-04 (Prescription Drug Prices and
`Medicare), adopted as official CMA policy 2004
`
`Author of CMA House of Delegates Resolution on Educating Primary Care
`Physicians on Developmental Disorders, adopted as official CMA policy 2005
`
`
`
`
`
`
`
`American Medical Association:
`
` Guest Participant, Relative Value Scale Update Committee, 2003
`
`Author of AMA House of Delegates Resolution A04-211 (Prescription Drug
`Prices and Medicare), adopted as official AMA policy 2004
`
`
`
`
`
`
`
`Author of AMA House of Delegates Resolution A05-419 (Physician Education
`On Developmental Disorders), adopted as official AMA policy 2005
`
`
`Medical Board of California:
`
` Medical Expert in Ophthalmology, 1999
`
`American Board of Ophthalmology:
`
`0005
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Associate Examiner, 1997-present.
`
`
`
`
`San Francisco Medical Society
`
`
`
`
`
`Board Member, 2009-2014
`
`Political Action Committee Board Member, 2009-2014; Board Consultant, 2015-
`present
`
`Executive Committee, 2011, 2013
`
`Political Action Committee Board Chair, 2011-2013
`
`
`
`
`
`
`
`Prevent Blindness Northern California (formerly Northern California Society to
`Prevent Blindness)
`
`Chairperson, 2011-2012
`
`Board Member, 1993-1999, 2004-2013
`
`
`
`
`
`
`
`
`
`
`
`CPMC-St. Luke's Campus (formerly St. Luke’s Hospital):
`
`Nominating Committee, 1997
`
`Eye Safety Committee, 1998
`
` Chief, Division of Ophthalmology, 1995-1999, 2001- 2010
`
` Institutional Review Board, 1996-2008
`
` Surgical Quality Improvement Committee, 1995-1999
`
` Operating Room Committee, 1995-1997
`
`Pacific Eye Physicians Medical Associates:
`
`
`
`President, 1997-1999. Served as CEO of Bay Area’s largest ophthalmology IPA,
`with over 200 ophthalmologists. Administered medical-surgical eyecare contracts
`covering 65,000 patient lives.
`
`0006
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Secretary, 1995-1997
`
` Board of Directors, 1994-2013
`
`University of California, San Francisco:
`
` Search Committee for Chief of Ophthalmology, VA Hospital, 2004-2005
`
`Buena Vista Specialty Medical Group:
`
` Board of Directors, 1997-1999
`
` Chairman, Credentials Committee, 1996-1999
`
`Frederick C. Cordes Eye Society:
`
` Treasurer, 1999-2002
`
`
`Campus Surgery Center:
`
` Board of Directors, 2015-present
`
`Archives of Ophthalmology:
`
` Reviewer, 2004
`
`Carl Zeiss Instruments:
`
`
`
`Consultant, 2011-present. Clinical consultant for development of software for
`optical coherence tomography for patients with glaucoma and retinal disease;
`consultant regarding specifications for a new-generation autorefractor
`incorporating comprehensive evaluation for cataract patients.
`
`
`
`
`Admitting Privileges:
`
`
`
`
`CPMC-St. Luke's Hospital, San Francisco, CA -- active
`
`
`
`
`0007
`
`

`

`California Pacific Medical Center, San Francisco, CA -- teaching
`
`University of California, San Francisco, CA -- teaching
`
`San Francisco General Hospital, San Francisco, CA -- courtesy
`
`St. Mary's Hospital, San Francisco, CA -- courtesy
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Awards and Scholarships:
`
`
`
`
`
`
`
`
`
`
`
`
`Seton Medical Center, Daly City, CA – courtesy
`
`Campus Surgery Center, Daly City, CA – active
`
`Chinese Hospital, San Francisco, CA -- courtesy
`
`American Academy of Ophthalmology Achievement Award, 2009
`
`American Academy of Ophthalmology Special Recognition Award, 2013
`
`Edwin E. Osgood Award: best student research in Western United States, 1988
`
`Genetics Subspecialty Award: best student research in genetics in Western United States,
`1988
`
`NIH Medical Scientist Training Program, 1982-1989
`
`Fred Gellert Foundation Scholarship 1986
`
`Achievement Rewards for College Scientists Foundation Scholarship 1985-1988
`
`Markey Foundation Scholarship 1984-1988
`
`Howard Hughes Medical Institute Summer Research Fellowship 1983
`
`Yale University Summer Research Fellowship 1982
`
`Temple University Summer Research Fellowship 1979-1981
`
`
`
`
`Publications:
`
`
`
`
`0008
`
`

`

`
`
`
`
`
`
`
`
`1. Charles P. Ordahl, Thomas Cooper, Catherine E. Ovitt, James A. Fornwald, Andrew F.
`Calman, and Arnold I. Caplan. "Molecular cloning and analysis of genes regulated
`during embryonic muscle differentiation." In Muscle Development: Molecular and
`Cellular Control, edited by Mark L. Pearson and Henry F. Epstein. New York: Cold
`Spring Harbor Press (1982), pp. 225-236.
`
`2. Pamela S. Ohashi, Tak W. Mak, Peter van den Elsen, Yusuke Yanagi, Yasunobu
`Yoshikai, Andrew F. Calman, Cox Terhorst, John D. Stobo, and Arthur Weiss.
`"Reconstitution of an active surface T3/T-cell antigen receptor by DNA transfer." Nature
`316:606-609 (1985).
`
`3. Andrew F. Calman and B. Matija Peterlin. "Expression of T cell receptor genes in
`human B cells." J. Exp. Med. 164:1940-1957 (1986).
`
`4. Kate E. Sullivan, Andrew F. Calman, Mikiye Nakanishi, Sue Y. Tsang, Yao Wang, and
`B. Matija Peterlin. "A model for the transcriptional regulation of MHC class II genes."
`Immunol. Today 8:289-293 (1987).
`
`5. Andrew F. Calman and B. Matija Peterlin. "Mutant human B cell lines deficient in
`class II MHC transcription." J. Immunol. 139:2489-2495 (1987).
`
`6. Shaw-Yi Kao, Andrew F. Calman, Paul A. Luciw, and B. Matija Peterlin. "HIV-1
`trans-activator (tat) functions as a transcriptional anti-terminator." Nature 330:489-493
`(1987).
`
`7. B. Matija Peterlin, Andrew F. Calman, Paul A. Luciw, Mark Selby, and Shaw-Yi Kao.
`"The mechanism of HIV-1 trans-activation." In Retroviruses of Human AIDS and
`Related Animal Diseases, edited by M. Girard and L. Valette. Lyon, France: Fondation
`Marcel Merieux (1987), pp. 85-89.
`
`8. B. Matija Peterlin, Andrew F. Calman, Shaw-Yi Kao, Mark J. Selby, Sandra E. Tong-
`Starksen, and Paul A. Luciw. "Transcriptional regulation of human immunodeficiency
`virus type 1." In Vaccines '88, edited by H. Ginsberg, F. Brown, R. A. Lerner, and R. M.
`Chanock. New York: Cold Spring Harbor Press (1988), pp. 283-290.
`
`9. Andrew F. Calman, Michael P. Busch, Girish N. Vyas, Thomas M. McHugh, Daniel P.
`Stites, and B. Matija Peterlin. "Transcription and replication of human
`immunodeficiency virus-1 in B lymphocytes in vitro." AIDS 2:185-193 (1988).
`
`10. B. Matija Peterlin, Andrew F. Calman, Shaw-Yi Kao, Mark Selby, Sandra Tong-
`Starksen, and Paul A. Luciw. "Activation and trans-activation of human
`immunodeficiency virus type 1." In The Control of Human Retrovirus Gene
`Expression, edited by B. R. Franza, Jr., B. R. Cullen, and F. Wong-Staal. New York:
`
`0009
`
`

`

`
`
`
`
`
`
`Cold Spring Harbor Press (1988), pp. 45-57.
`
`11. Andrew F. Calman and B. Matija Peterlin. "Evidence for a trans-acting factor that
`regulates the transcription of class II major histocompatibility complex genes: genetic
`and functional analysis." Proc. Natl. Acad. Sci. USA 85:8830-8834 (1988).
`
`12. Andrew F. Calman and B. Matija Peterlin. "Transcriptional regulation of HLA class
`II genes: cis-acting elements and trans-acting factors." In Molecular Biology of HLA
`Class II Antigens, edited by Jack Silver. Boca Raton, Florida: CRC Press (1990), pp.
`225-246.
`
`13. Robert T. Lee, Craig L. Peterson, Andrew F. Calman, Ira Herskowitz, and James J.
`O'Donnell. "Cloning of a human galactokinase gene (GK2) on chromosome 15 by
`complementation in yeast." Proc. Natl. Acad. Sci. USA 89:10887-10891 (1992).
`
`14. Andrew F. Calman. “Governor Howard Dean, MD, on Health Care and Politics.”
`San Francisco Medicine 76 (10):28-29 (2004).
`
`15. Andrew F. Calman. “Medicare’s New Prescription Drug Benefit: The Good, the Bad,
`and the Incomprehensible.” San Francisco Medicine 77 (3):18-20 (2004).
`
`16. Andrew F. Calman. “Medicare HMO’s: Whose Advantage?” San Francisco
`Medicine 77 (6):15-17 (2004).
`
`17. Andrew F. Calman. “A Medicare Smorgasbord: Part III” San Francisco Medicine
`77 (7):11-12 (2004).
`
`18. E.C. Strauss, A.J. Aldave, W.H. Spencer, B.C. Branco, D.A. Barsness, A.F. Calman,
`and T.P. Margolis. “Management of prominent iris vascular tufts causing recurrent
`spontaneous hyphema.” Cornea 24(2):224-226 (2005).
`
`19. Andrew F. Calman. “Obamacare: Past, Present, and Future” San Francisco
`Medicine 85(8):12-15 (2012).
`
`20. Andrew F. Calman and Steve Heilig. “The ACA, Your Practice, and You” San
`Francisco Medicine 87(1):8-9 (2014).
`
`21. Aim-on Saengsirinavin and Andrew F. Calman. “Multimodal Imaging of Purtscher-
`like retinopathy.” Ophthalmology Retina 1(3):255 (2017).
`
`Aim-on Saengsirinavin and Andrew F. Calman. “Idiopathic juxtafoveal macular
`telangiectasia type 3 with cerebral angiopathy.” Manuscript in preparation.
`
`Maria Ferreira and Andrew F. Calman. “Compressive optic neuropathy by parachiasmal
`
`0010
`
`

`

`
`
`
`vasculature mimicking normal-tension glaucoma.” Manuscript in preparation.
`
`
`
`
`
`Clinical Research:
`
`
`
`Clinical Investigator, NIH Aminoguanidine Treatment Trial: “A Placebo-Controlled
`Safety and Efficacy Study of Pimagedine in Patients with Type II Diabetes Mellitus and
`Overt Diabetic Nephropathy” (Pimagedine Protocol 201228PR0009), Marion Merrell
`Dow, Phase II and III, 1995-1997.
`
`Clinical Investigator, “28-week Multicenter, Controlled, Randomized, Open-Label
`Clinical Trial Comparing HOE-901 Insulin with NPH Human Insulin in Subjects with
`Type I Diabetes” (HOE 901/3004), Hoechst Marion Roussel, Phase III, 1997-1998.
`
`Clinical Investigator, “28-week Multicenter, Controlled, Randomized, Open-Label
`Clinical Trial Comparing HOE-901 Insulin with NPH Human Insulin in Subjects with
`Type II Diabetes” (HOE 901/3006), Hoechst Marion Roussel, Phase III, 1997-1998.
`
`Clinical Investigator, “A Clinical Evaluation of Alphagan (Brimonidine Tartrate
`Ophthalmic Solution 0.2%) in Patients with Open-Angle Glaucoma or Ocular
`Hypertension,” (Alphagan Clinical Evaluation 98/99 Glaucoma Trial), Allergan, 1998-
`1999.
`
`Clinical Investigator, “Lumigan Early Experience Data (LEED Study)”, Allergan, 2001.
`
`Clinical Investigator, “A Four-Week Primary Therapy Study to Compare IOP-Lowering
`Efficacy of Travatan 0.004% in African-American Patients with Open-Angle Glaucoma
`or Ocular Hypertension Previously Treated with Latanoprost 0.005%,” Alcon, 2001.
`
`Clinical Investigator, FDA Phase III Clinical Trial, “Success of Therapy of Switching to
`Latanoprost from Previously Failed Monotherapy,” Pharmacia, 2000-2001.
`
`Clinical Investigator, “Study of Travatan as Replacement Therapy,” Alcon, 2001.
`
`Clinical Investigator, FDA Phase III Clinical Trial, “A Multicenter, Double-Masked,
`Randomized, 3-Arm Parallel Study, for 3 Months (With a 9-Month, Masked Extension)
`of the Safety and Efficacy of Bimatoprost 0.03%/Timolol 0.5% Combination Ophthalmic
`Solution Once Daily Compared with Timolol 0.5% Monotherapy Twice Daily and
`Bimatoprost 0.03% Monotherapy Once Daily in Patients with Glaucoma or Ocular
`Hypertension,” Protocol No. 192024-018T-00, Allergan, 2001-2002.
`
`Clinical Investigator, “019T Alphagan-Timolol Study”, Allergan, 2003.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`0011
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`Clinical Investigator, “Internet Registry of Patients with Ocular Hypertension Treated
`with Xalatan (Project XOHT). Pharmacia, 2003-2005.
`
`Clinical Investigator, CUV039 Multicentre Phase III EPP Study 3
`A Phase III, Multicentre, Double-Blind, Randomized, Placebo-Controlled Study to
`Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants
`in Patients with Erythropoietic Protoporphyria (EPP) Clinuvel, 2012.
`
`
`Inventions:
`
`
`Calman-Chang Mega-Chopper: optimized surgical instrument for removal of dense
`cataracts. Prototype developed by Rhein Medical Instruments, 2005. Available through
`Rhein Medical Instruments (no financial interest).
`
`
`
`
`Teaching Experience:
`
`
`
`
`
`Outpatient clinical and surgical instructor to CPMC ophthalmology residents, beginning
`July 2010
`
`Surgical instructor to UCSF Ophthalmology residents at San Francisco General Hospital
`(approx. 10-60 hours per year), 1993-2012
`
`Surgical instructor to UCSF Ophthalmology residents at Veterans Administration Medical
`Center Ft. Miley (approx. 40 hours per year), 2003-2006
`
`Attending physician for UCSF Ophthalmology residents at UCSF Eye Clinic (approx. 10-
`40 hours per year), 1993-present
`
`Attending physician for UCSF Ophthalmology residents at San Francisco General
`Hospital Eye Clinic (approx. 20-40 hours per year), 2013-present
`
`Training of UCSF Family & Community Medicine and Internal Medicine residents in
`basic recognition of eye disease (approx. 50-150 hours per year), 1993-1995, 2006-2012
`
`Training of UCSF medical students in basic recognition of eye disease (approx. 10-100
`hours per year), 1993-1996, 1999-2011, 2013-present
`
`
`
`
`0012
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Invited Lecturer, UCSF Family Medicine Board Review Course, 2005-2013
`
`Invited Lecturer, Ocular Symposium, San Francisco, CA, 1995-2005, 2014
`
`Guest lecturer, UCSF Continuing Medical Education Course on Ocular and Periocular
`Malignancies, 1988
`
`Lecturer, UCSF graduate school immunology course, 1987
`
`Teaching assistant, UCSF medical school immunology course, 1987
`
`Tutor, UCSF medical school biochemistry course, 1982-1983
`
`Organizer and director, Amity/NCET MCAT Course, Berkeley, CA, 1982-1985
`(lectured in biology and chemistry; wrote workbook and revised textbook used
`nationwide in Amity/NCET MCAT Course)
`
`Biology lecturer, Amity MCAT Course, New Haven, CT, 1981-1982
`
`
`Community Service:
`
`
`
`
`
`
`Commissioner, San Mateo County Commission on Aging, 2003
`
`Church Council, Coastside Lutheran Church, 2007-2010
`
`
`
`
`
`
`
`Co-Chair, Children and Youth Workgroup, San Mateo County Mental Health Services
`Act Implementation Steering Committee, 2005-2006
`
`Board Member, San Mateo County Mental Health Board, 2003-2006
`
`San Mateo County Citizens Academy, 2003
`
`Neighborhood Organizer, FOCUS (Friends of Cabrillo Unified Schools) Measure C
`Campaign, 2003; Measure D Campaign, 2014
`
`Medical Advisory Board, National Association of the Visually Handicapped,
`1995-1998
`
`Medical Advisory Board, St. Luke's Diabetes Center, 1995-1997
`
`Volunteer Physician, National Eye Care Project, 1993-present
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`0013
`
`

`

`
`
`
`
`
`
`
`
`Pianist, United Way charity concerts, 1993
`
`Volunteer, Mission Neighborhood Health Fair, 1983, 1988, 1992
`
`Volunteer, UCSF Career Day specialty panel, 1994-1995
`
`
`
`Other Experience:
`
`
`
`Certified Retinal Photographer, Fundus Photograph Reading Center, 1995-present
`
`UCSF Surgical Laser Science and Safety Course, 1990
`
` Resident representative, Dean's committee on ophthalmology residency, 1993
`
`Student representative, Microbiology/Immunology Graduate Program Steering
`Committee, 1987
`
`Scientific Consultant, Clontech, Inc., Palo Alto, CA, 1986-1987
`
`Slavyanka Men’s Slavic Chorus, 1982-2003, 2009-2012, 2014 (Russia tour 1986,
`Rachmaninoff Vespers 1988 and 2001, recorded 3 CD’s)
`
`Yale Russian Chorus 1979-1982 (Carnegie Hall Concerts 1980 and 1981, RussiaTour
`1982, 50th Anniversary Concert 2003, 55th Anniversary Concert 2008)
`
` Masterworks Serenade Choir, 2008-2012
`
`Licensed private pilot, 1977-present
`
`Civil Air Patrol 1986-1988
`
`
`
`Society Memberships:
`
`
`
`
`
`
`
`
`
`California Medical Association, 1982-present
`
`San Francisco Medical Society, 1994-present
`
`American Academy of Ophthalmology, 1991-present
`
`
`
`
`0014
`
`

`

`California Academy of Eye Physicians and Surgeons (formerly California Academy of
`Ophthalmology), 1992-present
`
`Alpha Omega Alpha Honor Medical Society, 1988-present
`
`Association of the Clinical Faculty, UCSF, 1993-present
`
`Frederick C. Cordes Eye Society, 1990-2012
`
`American Diabetes Association, Professional Section, 1996-1999
`
`American Association for the Advancement of Science, 1984-1990, 1999-2001, 2003-
`2011
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`0015
`
`